The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
It would be “absurd” and a “travesty” for Indiana not to expand its Medicaid program, according to two local hospital officials. And yet other health care leaders do not expect expanded Medicaid coverage to provide nearly as much help to uninsured Hoosiers as hoped.
The 7th U.S. Circuit Court of Appeals in Chicago upheld a preliminary injunction that blocked the Indiana Family and Social Services Administration from enforcing a $1,000 annual limit on dental coverage. The agency had established it as a cost-cutting measure in 2011.
With health insurance premiums continuing to outstrip inflation, some health insurers and hospital systems are considering bringing back an old strategy: limiting patient access to a “narrow” network of doctors and hospitals.
The Fairbanks Foundation last year gave IU $20 million to help establish the Richard M. Fairbanks School of Public Health, which evolved from the Department of Public Health in the IU School of Medicine.
There will be health care rationing. The only question is who will do the rationing—the government, health care providers, or you and me. The odds are good there will be some rationing from all those sources
A friend recently asked me, “What’s the connection between healthy communities and economic development?” I set out to explain why no community can compete in today’s economy without healthy brainpower.
The looming shortage of nurses and the faculty to educate nurses threatens Americans’ access to quality health care. As our population ages and health care becomes more extensive and complex, an increasing demand for highly educated nurses persists. This need directly influences the necessity for nursing faculty.
Regenstrief study finds many visit two different facilities within year’s time.
While WellPoint Inc. and its predecessors have a history of grooming new CEOs in-house, the next leader of the health insurance giant is likely to be an outsider, according to interviews with more than a half dozen former directors and officers of the company.
Federal and state prosecutors have collected more than $30 billion from drug companies for alleged fraud and illegal marketing over the last 20 years, according to a new report by consumer advocacy group Public Citizen.
Chicago-based recruiting firm Spencer Stuart & Associates Ltd. has previously led executive and board director hunts for companies including Facebook Inc., Comcast Corp., Talbots Inc. and Hewlett-Packard Co.
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
If Indiana expands its Medicaid program as called for under President Obama’s health reform law, it likely will hike state spending on the program an extra 13.5 percent—or $516 million annually—by 2020, according to the latest projections from Seattle-based actuarial firm Milliman Inc.
Novo Nordisk A/S, the world’s largest insulin maker, plans to spend $100 million on research in China. The move follows a similar one by Indianapolis-based Eli Lilly, which opened a 150-person research center in Shanghai in May.
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
WellPoint is seeking a replacement for former CEO Angela Braly, who stepped down Aug. 28 amid shareholder discontent. The company plans to hire a search firm within the next week.
Mainstreet Property Group LLC plans to build a 100-bed facility at 16th Street and Arlington Avenue on nine acres where Raytheon Technical Services Co. LLC once operated.
Indiana Gov. Mitch Daniels' team of federal health care overhaul leaders told state lawmakers Wednesday that even without clear answers on the new law, it will cost the state hundreds of millions more in the coming years.
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
